Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Metabolism of sumatriptan revisited
View through CrossRef
AbstractScientific literature describes that sumatriptan is metabolized by oxidative deamination of its dimethylaminoethyl residue by monoamine oxidase A (MAO A) and not by cytochrome P450 (CYP)‐mediated demethylation, as is usual for such structural elements. Using recombinant human enzymes and HPLC‐MS analysis, we found that CYP enzymes may also be involved in the metabolism of sumatriptan. The CYP1A2, CYP2C19, and CYP2D6 isoforms converted this drug into N‐desmethyl sumatriptan, which was further demethylated to N,N‐didesmethyl sumatriptan by CYP1A2 and CYP2D6. Otherwise, sumatriptan and its two desmethyl metabolites were metabolized by recombinant MAO A but not by MAO B to the corresponding acetaldehyde, with sumatriptan being only a poor substrate for MAO A compared to the N‐demethylated and the N,N‐didemethylated derivatives.
Title: Metabolism of sumatriptan revisited
Description:
AbstractScientific literature describes that sumatriptan is metabolized by oxidative deamination of its dimethylaminoethyl residue by monoamine oxidase A (MAO A) and not by cytochrome P450 (CYP)‐mediated demethylation, as is usual for such structural elements.
Using recombinant human enzymes and HPLC‐MS analysis, we found that CYP enzymes may also be involved in the metabolism of sumatriptan.
The CYP1A2, CYP2C19, and CYP2D6 isoforms converted this drug into N‐desmethyl sumatriptan, which was further demethylated to N,N‐didesmethyl sumatriptan by CYP1A2 and CYP2D6.
Otherwise, sumatriptan and its two desmethyl metabolites were metabolized by recombinant MAO A but not by MAO B to the corresponding acetaldehyde, with sumatriptan being only a poor substrate for MAO A compared to the N‐demethylated and the N,N‐didemethylated derivatives.
Related Results
Sumatriptan activates TRPA1
Sumatriptan activates TRPA1
Background: Migraine therapy with sumatriptan may cause adverse side effects like pain at the injection site, muscle pain, and transient aggravation of headaches. In animal experim...
Sumatriptan Increases Skin Flap Survival through Activation of 5-Hydroxytryptamine 1b/1d Receptors in Rats: The Mediating Role of the Nitric Oxide Pathway
Sumatriptan Increases Skin Flap Survival through Activation of 5-Hydroxytryptamine 1b/1d Receptors in Rats: The Mediating Role of the Nitric Oxide Pathway
Background:
Random pattern skin flaps are applicable for reconstructing any defect in plastic surgery. However, they are difficult to apply because of necrosis. Sumatri...
Prolonged Migraine Aura Without Headache Arrested by Sumatriptan. A Case Report with Further Considerations
Prolonged Migraine Aura Without Headache Arrested by Sumatriptan. A Case Report with Further Considerations
The case of a 42-year-old woman with prolonged migraine visual aura without headache, whose long-lasting episodes of visual aura were successfully controlled by oral sumatriptan, i...
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
Receptor specificity and trigemino‐vascular inhibitory actions of a novel 5‐HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)
311C90 (zolmitriptan zomig: (S)‐4[[3‐[2‐(dimethylamino)ethyl]‐1H‐indol‐5‐yl]methyl]‐2‐oxazolidinone) is a novel 5‐HT1B/1D receptor agonist with proven efficacy in the acute treatme...
Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs
Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs
Background
—The antimigraine drugs ergotamine and sumatriptan may cause angina-like symptoms, possibly resulting from coronary artery constriction. We compared the coro...
Valdecoxib for Treatment of a Single, Acute, Moderate to Severe Migraine Headache
Valdecoxib for Treatment of a Single, Acute, Moderate to Severe Migraine Headache
Objective.—To evaluate the analgesic efficacy and safety of a single 20‐ or 40‐mg dose of valdecoxib compared with placebo in treatment of a single, acute, moderate or severe migra...
DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study
DFN‐02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double‐Blind, Placebo‐Controlled Study
Objective
The objective of this study was to evaluate the efficacy, safety, and tolerability of DFN‐02 — a nasal spray comprising sumatriptan 10 mg and a permea...
Study on non-targeted metabolomics of intestinal tract of DEV- infected ducks
Study on non-targeted metabolomics of intestinal tract of DEV- infected ducks
Abstract
Introduction
Duck enteritis virus (DEV) mainly causes infectious diseases characterized by intestinal hemorrhage, inflammation and parenchymal organ degeneration i...